Vizgen Unveils MERFISH 2.0 and Enhanced OmniVUE Panels with ADC Biomarkers
Vizgen, Inc., a pioneer in spatial genomics and proteomics, has announced the global commercial launch of MERFISH 2.0™, a next-generation spatial transcriptomics chemistry set to redefine the boundaries of biological discovery. Alongside this, the company is also expanding its OmniVUE™ spatial proteomics panels, now featuring validated ADC (Antibody-Drug Conjugate) biomarkers to support drug development and translational research.
Both innovations will be featured in a new multi-omics study that Vizgen is presenting at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25–30, 2025.
“With MERFISH 2.0 and our expanded OmniVUE panels, Vizgen is launching a new product cycle to drive deeper biological insight,” said Rob Carson, CEO of Vizgen. “We’re bringing transcriptomic and proteomic data together into complementary solutions that support discovery and therapeutic development across fields like oncology, neuroscience, and immunology.”
MERFISH 2.0: Elevating Spatial Transcriptomics
MERFISH 2.0™ builds on Vizgen’s widely adopted MERFISH (Multiplexed Error-Robust Fluorescence In Situ Hybridization) technology, which is already referenced in hundreds of peer-reviewed publications. The updated chemistry features improved RNA anchoring, optimized probe design, and enhanced signal amplification, resulting in higher sensitivity and reproducibility across a wider variety of tissue types.
This breakthrough allows for significantly increased transcript detection—up to 10 times more transcripts per field of view—along with more detailed subcellular localization, rare cell identification, and high-resolution cell type mapping.
“MERFISH 2.0 gives us the power to detect more transcripts and visualize intricate neuronal structures in unprecedented detail,” said Dr. Mathieu Bourdenx, Senior Research Fellow at University College London and the UK Dementia Research Institute. “It’s the most informative spatial transcriptomics dataset I’ve worked with, offering remarkable resolution for defining cell types and understanding complex biological systems.”
MERFISH 2.0 is fully compatible with Vizgen’s MERSCOPE® and MERSCOPE Ultra™ platforms, allowing researchers to integrate it seamlessly into ongoing projects. It also supports challenging sample types, including archived FFPE tissues, making it a valuable tool for retrospective and longitudinal studies.
Expanded OmniVUE Panels: Powering ADC Therapeutic Development
Alongside MERFISH 2.0, Vizgen is broadening its OmniVUE™ spatial proteomics portfolio with enhanced panels tailored for ADC biomarker research. These new additions are optimized for use with Vizgen’s InSituPlex® multiplex immunohistochemistry and STARVUE™ image data science platform, offering a scalable and customizable solution for high-fidelity, tissue-based biomarker analysis.
The expanded panels help researchers:
- Validate ADC targets with spatial precision.
- Conduct quantitative biomarker detection.
- Accelerate clinical translation of ADC therapies.
“As a GLP/GCP-compliant CRO specializing in biomarker analysis, Vizgen’s InSituPlex and STARVUE tools have transformed how we explore the tumor-immune microenvironment,” said Peter De’Ath, Head of Client Account Management at HistologiX. “The OmniVUE panels deliver rich, high-quality data with a streamlined workflow while preserving tissue integrity—critical for both early discovery and regulated research.”
The ADC biomarkers included in OmniVUE panels are carefully selected and validated to support a comprehensive biomarker strategy roadmap—an essential component for advancing next-generation immunotherapies and precision oncology.
A New Era for Spatial Multi-Omics
Vizgen’s integrated multi-omics approach is designed to bring transcriptomic and proteomic data together in a way that reveals complex tissue dynamics and biological relationships. By combining MERFISH 2.0’s deep spatial transcriptomics capabilities with OmniVUE’s high-throughput proteomic analysis, researchers can unlock new layers of biological insight with unprecedented resolution.
“With these tools, we’re enabling scientists to go from ‘samples to insights’ in ways that were previously impossible,” Carson added. “This is about equipping the scientific community with the best possible tools to understand disease and drive new therapies forward.”
Both MERFISH 2.0 and the updated OmniVUE panels are now available globally, giving researchers across academia and industry powerful new options for discovery science and translational research.
About Vizgen
Vizgen is a life sciences company at the forefront of spatial genomics and proteomics, delivering innovative tools for spatially resolved, high-resolution biological analysis. With platforms like MERSCOPE, MERFISH, and OmniVUE, Vizgen empowers researchers to uncover the molecular underpinnings of health and disease at the cellular level.
